Description

PGlu-3-methyl-His-Pro-NH2 TFA (A-42872 TFA), the modified thyrotropin-releasing hormone (TRH) peptide, enhances binding to pituitary TRH receptors and increases stimulation of thyroid-stimulating hormone (TSH) release from the pituitary. The in vitro permeability of PGlu-3-methyl-His-Pro-NH2 TFA through rat skin is increased in the presence of enhancers Ethanol and Cineole[1][2].–80°C, 2 years; -20°C, 1 year (Powder, sealed storage, away from moisture)—-C19H25F3N6O6—-[1]Koskinen LO, et al. Cerebrovascular effects of the TRH analogues pGlu-3-methyl-His-Pro amide and pGlu-Glu-Pro amide: a comparison with TRH. Ups J Med Sci. 2000;105(1):73-83.|[2]Magnusson BM, et al. Biological effects after percutaneous absorption of thyrotropin-releasing hormone and its analogue M-TRH. Peptides. 2001 Jan;22(1):73-9.—-490.43–99.69–CN1C(C[C@H](NC([C@@H](N2)CCC2=O)=O)C(N3[C@@H](CCC3)C(N)=O)=O)=CN=C1.OC(C(F)(F)F)=O–Endocrinology–DMSO : 100 mg/mL (ultrasonic)|H2O : 250 mg/mL (ultrasonic)–Others—-Others–Peptides